Telemedicine Boom Awaits Cost Studies

Telemedicine, or the use of telecommunications and information technology to deliver clinical health-care services, has become a fixture in some rural hospitals in the United States. Much of this presence is due to heavy government subsidies and grants, which leaves health officials unsure if telemedicine is cost-effective in these clinical settings. Other barriers-legal, financial, and technological-have limited its widespread use, and some critics charge that telemedicine is an unwise investm

Written byStephen Hoffert
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

Telemedicine, or the use of telecommunications and information technology to deliver clinical health-care services, has become a fixture in some rural hospitals in the United States. Much of this presence is due to heavy government subsidies and grants, which leaves health officials unsure if telemedicine is cost-effective in these clinical settings. Other barriers-legal, financial, and technological-have limited its widespread use, and some critics charge that telemedicine is an unwise investment for improving public health.

BOTTOM LINE: NLM's donald Lindberg says better studies are needed to determine if telemedicine can work in clinical settings. Health officials note that telemedicine could have a positive impact on the research community. Using real-time teleconferencing equipment and the Internet, telemedicine allows rapid communication between investigators, speeds the translation of articles, and improves information access and education in developing countries. Telemedicine already is used in a variety of medical specialties, including telepsychiatry, teleophthalmology, telerehabilitation, and teledermatology. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies